PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth

Su, Yansheng; Liu, Na; Z, Guo; Wang, Guodong; Zheng, Jia; Wei, Ming; Wang, He; Yang, An‐Gang; Qin, Weijun; Wen, Weihong

doi:10.1016/j.canlet.2013.05.035

Cited by 31 publications

(16 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the key barrier in therapeutic application is how to specifically and efficiently transport siRNA to MM cell silencing specific gene in vivo. To date, researchers have designed several strategies for targeted delivery of siRNA to specific cell populations, such as using of specialized liposomes, [25][26][27] viral vectors, 28 and single-chain antibody-protamine fusion protein, [29][30][31][32][33] among which, single-chain antibody-protamine fusion protein delivery has the greatest potential for its observed efficiency of delivering siRNA to specific target cells and inducing the desired biological effect on those cells. 34 The single-chain antibody-protamine fusion protein can recognize and target cell membrane receptors by a Fab fragment, and has a strong nucleic acid binding ability by a fusing nucleic acid binding domain-protamine, being able to deliver siRNA to specific cells and silence specific genes efficiently.…”

Section: Discussionmentioning

confidence: 99%

Single-chain antibody–delivered Livin siRNA inhibits human malignant melanoma growth in vitro and in vivo

Wang

Yang

Wang³

et al. 2017

Tumour Biol.

View full text Add to dashboard Cite

Although gene therapy has brought new insights into the treatment of malignant melanoma, targeting delivery of nucleic acid which targets critical oncogene/anti-oncogene in vivo is still a bottleneck in the therapeutic application. Our previous in vitro studies have found that the oncogene Livin could serve as a potential molecular target by small interfering RNA for gene therapy of malignant melanoma. However, how to transport Livin small interfering RNA into malignant melanoma cells specifically and efficiently in vivo needs further investigation. Cumulative evidence has suggested that single-chain antibody-mediated small interfering RNA targeted delivery is an effective way to silence specific genes in human cancer cells. Indeed, this study designed a protamine-single-chain antibody fusion protein, anti-MM scFv-tP, to deliver Livin small interfering RNA into LiBr cells. Further experiments confirmed the induction of cell apoptosis and suppression of cell proliferation by anti-MM scFv-tP in LiBr cells, along with efficient silence of Livin gene both in vitro and in vivo. Altogether, our findings provide a feasible approach to transport Livin small interfering RNA to malignant melanoma cells which would be a new therapeutic strategy for combating malignant melanoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Single-chain antibody–delivered Livin siRNA inhibits human malignant melanoma growth in vitro and in vivo

Wang

Yang

Wang³

et al. 2017

Tumour Biol.

View full text Add to dashboard Cite

show abstract

“…The transport of biological effector molecules to cancer sites by antibody fragments is a commonly used targeted transport strategy [85][86][87]. Biological effector molecule short interfering RNA (siRNA) with silencing gene expression is a potential cancer therapeutic biologic [88,89]. However, when siRNA is used alone, it is easily degraded by serum and stimulates the immune system.…”

Section: Antibody Fragment Conjugated To Biological Effector Moleculesmentioning

confidence: 99%

A promising cancer diagnosis and treatment strategy: targeted cancer therapy and imaging based on antibody fragment

Zhao

Ning

Zhang

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

With the arrival of the precision medicine and personalized treatment era, targeted therapy that improves efficacy and reduces side effects has become the mainstream approach of cancer treatment. Antibody fragments that further enhance penetration and retain the most critical antigen-specific binding functions are considered the focus of research targeting cancer imaging and therapy. Thanks to the superior penetration and rapid blood clearance of antibody fragments, antibody fragment-based imaging agents enable efficient and sensitive imaging of tumour sites. In tumour-targeted therapy, antibody fragments can directly inhibit tumour proliferation and growth, serve as an ideal carrier for delivery of anti-tumour drugs, or manipulate the immune system to eliminate tumour cells. In this review, the excellent physicochemical properties and the basic structure of antibody fragments are expressly depicted depicted, the progress of antibody fragments in cancer therapy and imaging are thoroughly summarized, and the future development of antibody fragments is predicted.

show abstract

“…Recent studies indicate that siRNA mediated Notch1 knockdown inhibited invasion and proliferation of prostate cancer cells [116]. Down-regulation of Notch1 expression by a Notch1 targeting siRNA/PSAM-protamine inhibited tumor growth and increased apoptosis in a LNCaP subcutaneous murine xenograft model [117]. …”

Section: Current Targets For Sirna In Cancermentioning

confidence: 99%

Delivery strategies and potential targets for siRNA in major cancer types

Lee

Kim

Kwon

et al. 2016

Advanced Drug Delivery Reviews

119

View full text Add to dashboard Cite

Small interfering RNA (siRNA) has gained attention as a potential therapeutic reagent due to its ability to inhibit specific genes in many genetic diseases. For many years, studies of siRNA have progressively advanced toward novel treatment strategies against cancer. Cancer is caused by various mutations in hundreds of genes including both proto-oncogenes and tumor suppressor genes. In order to develop siRNAs as therapeutic agents for cancer treatment, delivery strategies for siRNA must be carefully designed and potential gene targets carefully selected for optimal anti-cancer effects. In this review, various modifications and delivery strategies for siRNA delivery are discussed. In addition, we present current thinking on target gene selection in major tumor types.

show abstract

PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth

Cited by 31 publications

References 43 publications

Single-chain antibody–delivered Livin siRNA inhibits human malignant melanoma growth in vitro and in vivo

Single-chain antibody–delivered Livin siRNA inhibits human malignant melanoma growth in vitro and in vivo

A promising cancer diagnosis and treatment strategy: targeted cancer therapy and imaging based on antibody fragment

Delivery strategies and potential targets for siRNA in major cancer types

Contact Info

Product

Resources

About